Also known as: CJC
Molecular Weight
3367.97 Da
Half-Life
30 minutes (no DAC) / 5.8-8.1 days (with DAC)
Administration
Subcutaneous injection
Longevity Score
8/10
A long-acting GHRH analog that produces dose-dependent increases in mean plasma GH concentrations (2-10 fold for 6+ days) and IGF-I levels (1.5-3 fold for 9-11 days). After multiple doses, IGF-I remains elevated for up to 28 days. Synergistic with GHRP peptides.
beginner
100mcg before bed (30µg/kg)
intermediate
200mcg before bed (60µg/kg)
advanced
200mcg 2x daily
athlete
200mcg before bed with Ipamorelin
Frequency: Daily (before bed) · Duration: 8–16 weeks continuous; best combined with Ipamorelin on same schedule
Week 1-2
Enhanced sleep quality, GH elevation
Week 3-4
Improved recovery and energy, IGF-1 sustained
Week 5-8
Body composition changes
Long Term
Sustained GH optimization, cumulative IGF-1 benefits
CJC-1295 pharmacokinetics study (2006)
Produced sustained 2-10 fold elevation in GH and 1.5-3 fold IGF-1 increase
DOI: 10.1210/jc.2005-2664Explore more peptides in this category
View All Growth Hormone Peptides →Research Disclaimer: This information is compiled from published research and is provided for educational purposes only. Peptides discussed here are classified as research chemicals in most jurisdictions and are not FDA-approved for human use unless otherwise noted. Consult a qualified healthcare provider before starting any protocol.